"Meridian Clinical Research studies the safety and efficacy of new treatments. When people like you participate in clinical trials, we can uncover better ways to treat conditions that may affect you and your loved ones. Meridian's Cincinnati Springdale site (formerly known as Sterling Research Group) conducts research for a broad range of investigational treatments. Studies at this site explore vaccines and medicines developed to treat migraines, acne, depression, high cholesterol, and other conditions. Visit our website to learn more about the clinical research process or find a research study near you."

During the past decade, Sterling Research Group, Ltd. conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 54 clinical trials were completed, i.e. on average, 114.9% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 31 clinical trials were completed. i.e. 182.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sterling Research Group, Ltd." #1 sponsor was "Pfizer" with 17 trials, followed by "LIB Therapeutics LLC" with 6 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored, "AstraZeneca" with 3 trials sponsored and "Iroko Pharmaceuticals, LLC" with 3 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sterling Research Group, Ltd." #1 collaborator was "Medpace, Inc." with 6 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "CTI Clinical Trial and Consulting Services" with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Sterling Research Group, Ltd." are "Hypercholesterolemia" (5 trials), "Osteoarthritis" (5 trials), "Cardiovascular Diseases" (4 trials), "Hyperlipidemia" (4 trials) and "Type 2 Diabetes Mellitus" (4 trials). Many other conditions were trialed in "Sterling Research Group, Ltd." in a lesser frequency.

Most popular intervention types in "Sterling Research Group, Ltd." are "Drug" (71 trials), "Biological" (15 trials), "Other" (10 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "lerodalcibep" (4 trials), "Dapagliflozin" (3 trials), "Fenofibrate" (3 trials) and "Saxagliptin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sterling Research Group, Ltd." are 86 trials for "All" genders.

Currently, there are NaN active trials in "Sterling Research Group, Ltd.". undefined are not yet recruiting, 1 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 66 completed trials in Sterling Research Group, Ltd., 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Sterling Research Group, Ltd., 0 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".